Advertisement

Deciphering the prognostic significance of autoimmune disorders in myelodysplastic syndromes

  • Claudio Fozza
Letter to the Editor
  • 12 Downloads

Dear Editor,

It is now clear that myelodysplastic syndromes (MDS) are associated with several immune abnormalities [ 1, 2] beside an increased frequency of autoimmune disorders (AD) [ 3]. Montoro and colleagues interestingly analysed the prevalence, clinical characteristics, and outcomes of 142 patients with MDS and AD showing that their overall survival (OS) was inferior even in multivariate analysis and this detrimental effect was confined to patients with clinical rather than laboratoristic manifestations [ 4]. Although these findings are extremely relevant, it is worth mentioning, as shown in Table 1, that the prognostic significance of AD in MDS patients is still debated. In fact, some more studies apparently suggested a potential negative prognostic impact. Among 153 patients, 19 of which developed AD, the survival of subjects with immune abnormalities was significantly worse, as these patients tended to die more frequently of infection or leukemic progression [ 5]. Among 117 MDS...

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Fozza C, Longinotti M (2012) Are T-cell dysfunctions the other side of the moon in the pathogenesis of myelodysplastic syndromes? Eur J Haematol 88(5):380–387CrossRefGoogle Scholar
  2. 2.
    Fozza C, Longu F, Contini S, Galleu A, Virdis P, Bonfigli S, Murineddu M, Gabbas A, Longinotti M (2012) Patients with early-stage myelodysplastic syndromes show increased frequency of CD4+CD25+CD127(low) regulatory T cells. Acta Haematol 128(3):178–182CrossRefGoogle Scholar
  3. 3.
    Fozza C (2018) The burden of autoimmunity in myelodysplastic syndromes. Hematol Oncol 36:15–23CrossRefGoogle Scholar
  4. 4.
    Montoro J, Gallur L, Merchán B, Molero A, Roldán E, Martínez-Valle F, Villacampa G, Navarrete M, Ortega M, Castellví J, Saumell S, Bobillo S, Bosch F, Valcárcel D (2018) Autoimmune disorders are common in myelodysplastic syndrome patients and confer an adverse impact on outcomes. Ann Hematol 97(8):1349–1356CrossRefGoogle Scholar
  5. 5.
    Okamoto T, Okada M, Mori A et al (1997) Correlation between immunological abnormalities and prognosis in myelodysplastic syndrome patients. Int J Hematol 66(3):345–351CrossRefGoogle Scholar
  6. 6.
    Zhao S, Mao H, Wang H, Yu J (2002) The relationship between myelodysplastic syndromes and autoimmune disorders. Zhonghua Xue Ye Xue Za Zhi 23(6):311–313PubMedGoogle Scholar
  7. 7.
    de Hollanda A, Beucher A, Henrion D, Ghali A, Lavigne C, Lévesque H, Hamidou M, Subra JF, Ifrah N, Belizna C (2011) Systemic and immune manifestations in myelodysplasia: a multicenter retrospective study. Arthritis Care Res 63(8):1188–1194CrossRefGoogle Scholar
  8. 8.
    Lee SJ, Park JK, Lee EY, Joo SH, Jung KC, Lee EB, Song YW, Yoon SS (2016) Certain autoimmune manifestations are associated with distinctive karyotypes and outcomes in patients with myelodysplastic syndrome: a retrospective cohort study. Medicine (Baltimore) 95(13):e3091CrossRefGoogle Scholar
  9. 9.
    Giannouli S, Voulgarelis M, Zintzaras E, Tzioufas AG, Moutsopoulos HM (2004) Autoimmune phenomena in myelodysplastic syndromes: a 4-yr prospective study. Rheumatology (Oxford) 43(5):626–632CrossRefGoogle Scholar
  10. 10.
    Marisavljević D, Kraguljac N, Rolović Z (2006) Immunologic abnormalities in myelodysplastic syndromes: clinical features and characteristics of the lymphoid population. Med Oncol 23(3):385–391CrossRefGoogle Scholar
  11. 11.
    Mekinian A, Grignano E, Braun T, Decaux O, Liozon E, Costedoat-Chalumeau N, Kahn JE, Hamidou M, Park S, Puéchal X, Toussirot E, Falgarone G, Launay D, Morel N, Trouiller S, Mathian A, Gombert B, Schoindre Y, Lioger B, de Wazieres B, Amoura Z, Buchdaul AL, Georgin-Lavialle S, Dion J, Madaule S, Raffray L, Cathebras P, Piette JC, Rose C, Ziza JM, Lortholary O, Montestruc F, Omouri M, Denis G, Rossignol J, Nimubona S, Adès L, Gardin C, Fenaux P, Fain O (2016) Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study. Rheumatology (Oxford) 55(2):291–300CrossRefGoogle Scholar
  12. 12.
    Komrokji RS, Kulasekararaj A, Al Ali NH et al (2016) Autoimmune diseases and myelodysplastic syndromes. Am J Hematol 91(5):E280–E283CrossRefGoogle Scholar
  13. 13.
    Fozza C, Crobu V, Isoni MA, Dore F (2016) The immune landscape of myelodysplastic syndromes. Crit Rev Oncol Hematol 107:90–99CrossRefGoogle Scholar
  14. 14.
    Fozza C, Corda G, Barraqueddu F, Virdis P, Contini S, Galleu A, Isoni A, Dore F, Angelucci E, Longinotti M (2015) Azacitidine improves the T-cell repertoire in patients with myelodysplastic syndromes and acute myeloid leukemia with multilineage dysplasia. Leuk Res 39(9):957–963CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Medical, Surgical and Experimental SciencesUniversity of SassariSassariItaly

Personalised recommendations